The therapeutic potential of robust cGAS-STING pathway activation in GBM has been demonstrated by use of synthetic cGAMP as a STING agonist that promotes anti-tumor immunity, implicating both T cells and innate immune cells such as macrophages [33]. The gene discussed is STING1; the disease is neoplasm.